



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/632,039	07/31/2003	Szu-Min Lin	JJM-346CIP1	9647
27777	7590	11/13/2007		
PHILIP S. JOHNSON JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933-7003			EXAMINER JOYNER, KEVIN	
			ART UNIT	PAPER NUMBER
			1797	
			MAIL DATE	DELIVERY MODE
			11/13/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/632,039	Applicant(s) LIN ET AL.	
	Examiner Kevin C. Joyner	Art Unit 1797	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 18 October 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-8 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-8 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>10/18/07</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on October 18, 2007 has been entered:

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 1 and 6-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fry et al. (U.S. Patent No. 3893843) in view of Addy et. al. (U.S. Patent No. 5961921).

Fry discloses a method for cleaning and sterilizing a medical device (as disclosed in column 1 line 5), comprising the steps of: placing the device into a container (referenced as a tub in column 3 line 8); cleaning the device in the container with a cleaning solution (referenced as a washing liquid in column 3 line 15); and rinsing the

device in the container with a rinse solution (as disclosed in column 3 line 31). Fry does not appear to disclose vaporizing a liquid substance in the container to create a sterilant vapor and contacting the device with the vapor to effect sterilization of the device. Addy discloses methods for peroxide vapor sterilization of medical devices. The patent further discloses a method comprising the step of vaporizing a liquid substance in the container to create a sterilant vapor and contacting the device with the vapor to effect sterilization of the device (as disclosed in column 2 lines 54-58). It would have been obvious to one of ordinary skill in the art at the time of the invention to modify the method as shown by Fry to include the step of vaporizing a liquid substance in the container to create a sterilant vapor and contacting the device with the vapor to effect sterilization of the device in view of Addy in order to produce a sterile tool without the need of a final rinsing step.

Concerning the limitations of claims 6-8, Fry is relied upon as set forth in regards to claim 1. Fry does not appear to disclose a method wherein the liquid substance comprises a chemical sterilant and wherein the chemical sterilant comprises hydrogen peroxide, or a method further comprising introducing the liquid substance as a mist. Addy is relied as set forth in regards to claim 1, and further discloses a method wherein the liquid substance comprises a chemical sterilant and wherein the chemical sterilant comprises hydrogen peroxide (as disclosed in column 2, lines 59-61) as well as a method further comprising introducing the liquid substance as a mist (column 3, line 10 states that the introduction of the liquid substance can happen in a plurality of ways including aerosol spray. As broadly interpreted, an aerosol spray produces a mist.).

Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention for Fry to include the liquid substance comprising a chemical sterilant and wherein the chemical sterilant comprises hydrogen peroxide, which is a commonly known sterilizing chemical as exemplified by Addy.

3. Claim 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over Fry in view of Addy as applied to claim 1 above, and further in view of Langford (U.S. Patent No. 5,711,921).

Fry in view of Addy is relied upon as set forth in reference to claim 1. Fry in view of Addy does not appear to disclose a method according to claim 1 further comprising storing the device in the container in sterile form. Langford discloses a method with an improved apparatus, which can be used, for cleaning and/or sterilizing devices. The patent further discloses a method comprising storing the device in a container in sterile form (as disclosed in column 6, lines 32-37; the device is an endoscope). Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to modify the method as shown by Fry in view of Addy to include the step of storing the device in the container in sterile form as shown by Langford. This eliminates the need for transporting the sterilized device to a storing compartment thus reducing the chances for the device to become contaminated again.

4. Claim 3 is rejected under 35 U.S.C. 103(a) as being unpatentable over Fry in view of Addy as applied to claim 1 above, and further in view of Langford (U.S. Patent No. 5,443,801).

Fry in view of Addy is relied upon as set forth in reference to claim 1. Fry in view of Addy does not appear to disclose a method according to claim 1 wherein the liquid substance comprises a retained portion of the rinse solution. Mariotti discloses a method that includes a device for cleaning, disinfecting and/or drying an endoscope. The patent further states during one of the method steps that a liquid substance comprises a retained portion of a rinse solution (Column 8, paragraph 1 states that a disinfecting sequence takes place in two steps. The first is injected into a line, which is continually recycled through a recycling pump (more information on the recycling stream is disclosed in column 5, lines 28-39). As broadly interpreted, this is a rinsing step. The second step consists of adding a second dose of disinfectant to the stream of the first step, which makes up a liquid substance. As broadly interpreted, this discloses a liquid substance comprising a retained portion of a rinse solution.). Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to modify the method as shown by Fry and Addy to include a method step that a liquid substance comprises a retained portion of a rinse solution as shown by Mariotti. This would minimize the amount of material used during the sterilization process.

5. Claims 4 and 5 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fry in view of Addy as applied to claim 1 above, and further in view of McConnell et al. (U.S. Patent No. 4,917,123).

Fry in view of Addy is relied upon as set forth in reference to claim 1. Fry in view of Addy does not appear to disclose a method according to claim 1 wherein the rinse solution comprises a chemical sterilant and wherein the chemical sterilant comprises

hydrogen peroxide. McConnell discloses a method for the sterilization of wafers in which a rinse solution is used. The patent further discloses that a rinse solution comprises a chemical sterilant and wherein the chemical sterilant comprises hydrogen peroxide (as disclosed in column 16, lines 52-58). Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention to modify the method of Fry and Addy to include a rinse solution comprising a chemical sterilant and wherein the chemical sterilant comprises hydrogen peroxide. As exemplified by McConnell it is a commonly known chemical sterilant for rinsing.

Conclusion

6. All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then, the shortened statutory period will expire on the date the advisory action is mailed, and any

Application/Control Number:
10/632,039
Art Unit: 1797

Page 7


extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kevin C. Joyner whose telephone number is (571) 272-2709. The examiner can normally be reached on M-F 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gladys Corcoran can be reached on (571) 272-1214. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

KCJ


GLADYS JP CORCORAN
SUPERVISORY PATENT EXAMINER

Application/Control Number:
10/632,039
Art Unit: 1797

Page 8